@article{804ad795bc4640a7b2ee046ee9c474d7,
title = "Biomarkers of mineral metabolism and progression of aortic valve and mitral annular calcification: The Multi-Ethnic Study of Atherosclerosis",
abstract = "Background and aims: Previous research has implicated dysregulation of phosphate metabolism and calcium-phosphate solubilization in cardiovascular calcification, but epidemiologic studies evaluating longitudinal associations with valvular or annular calcification by computed tomography (CT), a highly sensitive imaging modality, are lacking. Our primary aim was to investigate the associations of mineral biomarkers with incidence and progression of aortic valve calcification (AVC)and mitral annular calcification (MAC). Methods: We evaluated the associations of serum FGF-23 (n = 6547 participants), phosphate (n = 6547), and fetuin-A (n = 2550)measured at baseline in the community-based Multi-Ethnic Study of Atherosclerosis with AVC and MAC on CT performed at baseline and at a median of 2.4 (1.6, 3.1)years later. We used linear mixed-effects models to account simultaneously for prevalence, incidence and progression of AVC and MAC. Results: After adjustment for demographic and clinical characteristics, a significant association was documented for FGF-23 with accelerated annual progression of MAC (2.83 Agatston units (AU), 95% CI = 0.49, 5.17 AU, per standard deviation (18.46 pg/mL)of FGF-23), but this was not seen for phosphate or fetuin-A. None of these biomarkers was associated with accelerated annual progression of AVC. Conclusions: This study provides evidence relating serum FGF-23 to accelerated annual MAC progression. Whether this mineral regulator is a risk marker or is involved in pathogenesis merits further investigation.",
keywords = "Fetuin-A, Fibroblast growth factor, Metabolism, Mineral, Valve",
author = "Bortnick, {Anna E.} and Shuo Xu and Kim, {Ryung S.} and Bryan Kestenbaum and Ix, {Joachim H.} and Jenny, {Nancy S.} and {de Boer}, {Ian H.} and Michos, {Erin D.} and George Thanassoulis and Siscovick, {David S.} and Budoff, {Matthew J.} and Kizer, {Jorge R.}",
note = "Funding Information: JRK reports stock ownership in Amgen, Gilead Sciences, Johnson & Johnson, and Pfizer. During 2017–18, AEB was a site principal investigator for multi-center trials funded by Abbott, AstraZeneca, CSL Behring, sanofi-aventis, and NIH for which her institution received compensation. The other authors have nothing to disclose.AEB recognizes support from the Empire Clinical Research Program, American Heart Association Mentored and Clinical Population Research Award 17MCPRP33630098, and National Center for Advancing Translational Sciences Einstein-Montefiore CTSA Grant UL1-TR-001073. JRK is supported by K24 HL135493 from the National Heart, Lung, and Blood Institute. IHdB acknowledges support from R01 DK096875 from the National Institute of Diabetes and Digestive and Kidney Diseases. This research was supported by R01 HL071739 and MESA was supported by contracts N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 from the National Heart, Lung, and Blood Institute, and by grants UL1-TR-000040, UL1-TR-001079, and UL1-RR-025005 from National Center for Research Resources. The authors thank the other investigators, the staff, and the participants of the MESA study for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.MESA-nhlbi.org. Funding Information: AEB recognizes support from the Empire Clinical Research Program , American Heart Association Mentored and Clinical Population Research Award 17MCPRP33630098, and National Center for Advancing Translational Sciences Einstein-Montefiore CTSA Grant UL1-TR-001073 . JRK is supported by K24 HL135493 from the National Heart, Lung, and Blood Institute . IHdB acknowledges support from R01 DK096875 from the National Institute of Diabetes and Digestive and Kidney Diseases. This research was supported by R01 HL071739 and MESA was supported by contracts N01-HC-95159 , N01-HC-95160 , N01-HC-95161 , N01-HC-95162 , N01-HC-95163 , N01-HC-95164 , N01-HC-95165 , N01-HC-95166 , N01-HC-95167 , N01-HC-95168 and N01-HC-95169 from the National Heart, Lung, and Blood Institute , and by grants UL1-TR-000040 , UL1-TR-001079 , and UL1-RR-025005 from National Center for Research Resources . The authors thank the other investigators, the staff, and the participants of the MESA study for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.MESA-nhlbi.org . Publisher Copyright: {\textcopyright} 2019",
year = "2019",
month = jun,
doi = "10.1016/j.atherosclerosis.2019.04.215",
language = "English (US)",
volume = "285",
pages = "79--86",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
}